This approach opened exciting opportunities for future usage of selective SIRT2 inhibitors in overcoming poor clinical response to the TIL (tumor-infiltrating lymphocyte) or CAR-T (chimeric antigen receptor–T cell) immunotherapies [14]. The gene discussed is SIRT2; the disease is neoplasm.